Crescendo Biologics

Crescendo has developed a novel antibody fragment platform which generates fully human VH products, the smallest antibody fragments, that mature in vivo in a transgenic mouse. The company has a highly experienced antibody drug discovery team and capability. Crescendo is using the platform to develop a portfolio of differentiated medicines, with an initial focus on novel topical products, and is identifying companies interested in partnering this platform during 2013.

Come and see us at booth #73

Mr Matthew Roe
Dr Mike Romanos